News Releases
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
Vancouver, Canada. November 17, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Grants Stock Options
Vancouver, Canada. November 15, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal females U.S. Food and Drug Administration
NervGen Engages Cloutier Consulting to Provide Media Relations Services
Vancouver, Canada. October 31, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen’s NVG-291
Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damage NervGen
NervGen Pharma Presenting at Upcoming Scientific Meetings
AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETING EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, Canada. October 20, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX:
NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen’s NVG-291-R for Peripheral Nerve Injury
The $1.5 million award is to evaluate the ability of NervGen’s NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI) The
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, September 29, 2022 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage
NervGen Pharma Announces Leadership Transition
Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Adam Rogers, member of the Board of Directors, appointed interim President
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Lukashev brings over 20 years’ experience including work at Biogen and
NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
Vancouver, Canada. September 08, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update
Cash position enhanced by over $22 million due to private placement and exercise of warrants and options Dosing in third dose cohort of multiple ascending
NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer’s Disease at the 2022 Alzheimer’s Association International Conference
Vancouver, Canada August 2, 2022 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair from a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke
NervGen Pharma Grants Stock Options
Vancouver, Canada. July 15, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing